EGFR and non-small cell lung carcinoma: NSCLC patients with EGFR&TP53 co-alterations showed similar responses to Gefitinib and Icotinib, and TP53 concomitant mutations might be a poor prognostic factor for patients with EGFR-mutation treated with Gefitinib.